Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncocyte Corp (NQ: OCX )

2.680 +0.010 (+0.36%)
Streaming Delayed Price Updated: 10:10 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,936
Open 2.650
Bid (Size) 2.710 (30)
Ask (Size) 2.790 (1)
Prev. Close 2.670
Today's Range 2.650 - 2.694
52wk Range 2.285 - 4.305
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024
OCX stock results show that OncoCyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Penny Stocks That Insiders Are Buying
Penny stocks are a risky business but following the insiders to your next trade can alleviate some of the risks; these are the three hottest insider buys. 
Via MarketBeat

Performance

YTD
-18.80%
-18.80%
1 Month
-13.00%
-13.00%
3 Month
-16.52%
-16.52%
6 Month
-5.46%
-5.46%
1 Year
-32.50%
-32.50%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
OncoCyte's Earnings: A Preview
Via Benzinga
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
Via ACCESSWIRE
Earnings Scheduled For November 12, 2024
Via Benzinga
What to Expect from OncoCyte's Earnings
Via Benzinga
OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
Via AB Newswire
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
Via News Direct
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
Via TheNewswire.com
4 Analysts Assess OncoCyte: What You Need To Know
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Top 3 Health Care Stocks That May Collapse In Q2
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Earnings Scheduled For April 12, 2024
Via Benzinga
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.